Indeed, scRNA-seq analysis of the impact of FA-TLR7-1A on the TME suggests that FRβ+ macrophages contribute prominently to tumor growth, and treatment of FRβ+ TAMs/MDSCs with a TLR7 agonist shifts them to a more inflammatory phenotype. The gene discussed is TLR7; the disease is neoplasm.